Egalet and Purdue reach patent settlement

23 May 2016

US specialty pharma firm Egalet (Nasdaq: EGLT) says it has reached an agreement with Purdue Pharma as it relates to alleged patent infringements against Egalet and product licensor Acura Pharmaceuticals (Nasdaq: ACUR) for Oxaydo (oxycodone HCl, USP) tablets CII.

In April 2015 and April 2016 Purdue Pharma LP, Purdue Pharmaceuticals LP and The PF Laboratories, filed patent infringement lawsuits against Egalet for Oxaydo alleging the product infringes Purdue's US Patent Nos 8,389,007 and 9,308,171, respectively.

Egalet license worldwide rights to Oxaydo, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from US specialty pharma firm Acura last year (The Pharma Letter January 9, 2015)

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK